Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Summary

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Timeline

Start

2012-10

Primary completion

2015-04

Completion

2015-04

Outcome

Mixed primary results

registry NUMBER Intervention: 68.0 percentage of patients NUMBER Control: 55.5 percentage of patients analysis (superiority or other test); Intervention vs Control; p = 0.002 NCT01703702 ↗

registry Mild Impairment AB+: 0.95 (Standard Error 0.38) units on a scale LEAST_SQUARES_MEAN Mild Impairment AB-: 1.29 (Standard Error 0.43) units on a scale analysis (superiority or other test); Mild Impairment AB+ vs Mild Impairment AB-; p = 0.568 NCT01703702 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	florbetapir F 18	Diagnostic / imaging agent	370 mbq	Intravenous

Indications